Stage IV Salivary Gland Cancer Completed Phase 2 Trials for Erlotinib (DB00530)

Also known as: Salivary gland cancer stage IV / Metastatic salivary gland cancer / Malignant salivary gland cancer stage IV

DBCOND0028780 (Stage IV Salivary Gland Cancer)Completed2 IdentifierTitlePurposeDrugs
NCT01316757Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell CancerTreatment